Trial · NCT07524101
Registered outcomes27
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 27
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Major adverse cardiovascular events | 3 years | Composite of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization. |
| Secondary | CKD progression | 3 years | CKD progression: ≥40% decline in eGFR from baseline, confirmed on at least two consecutive measurements during follow-up. |
| Secondary | Cardiovascular death. | 3 years | Death due to cardiovascular causes during follow-up. |
| Secondary | Myocardial infarction. | 3 years | Occurrence of myocardial infarction during follow-up. |
| Secondary | Stroke. | 3 years | Occurrence of stroke during follow-up |
| Secondary | Hospitalization for unstable angina. | 3 years | Hospitalization due to unstable angina during follow-up. |
| Secondary | Coronary revascularization. | 3 years | Any coronary revascularization procedure, including percutaneous coronary intervention or coronary artery bypass graft surgery, during follow-up. |
| Secondary | Composite of cardiovascular death, myocardial infarction, and stroke. | 3 years | First occurrence of cardiovascular death, myocardial infarction, or stroke during follow-up. |
| Secondary | Composite of cardiovascular death, myocardial infarction, stroke, and hospitalization for unstable angina | 3 years | First occurrence of cardiovascular death, myocardial infarction, stroke, or hospitalization for unstable angina during follow-up |
| Secondary | Composite of cardiovascular death, myocardial infarction, stroke, and coronary revascularization. | 3 years | First occurrence of cardiovascular death, myocardial infarction, stroke, or coronary revascularization during follow-up. |
| Secondary | Composite of all-cause death, myocardial infarction, stroke, hospitalization for unstable angina, and coronary revascularization. | 3 years | First occurrence of all-cause death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization during follow-up. |
| Secondary | Proportion of participants achieving the LDL-C <70 mg/dL in each group. | 3 years | Proportion of participants achieving a low-density lipoprotein cholesterol (LDL-C) level below 70 mg/dL in each treatment group during follow-up. |
| Secondary | Proportion of participants achieving LDL-C <55 mg/dL in each group. | 3 years | Proportion of participants achieving a low-density lipoprotein cholesterol (LDL-C) level below 55 mg/dL in each treatment group during follow-up. |
| Secondary | Proportion of participants crossing over to the non-assigned treatment group in each group. | 3 years | Proportion of participants who crossed over from the assigned treatment group to the non-assigned treatment group during follow-up. |
| Secondary | New-onset diabetes mellitus. | 3 years | Occurrence of new-onset diabetes mellitus during follow-up. |
| Secondary | New-onset diabetes mellitus requiring initiation of antidiabetic medication. | 3 years | Occurrence of new-onset diabetes mellitus requiring initiation of antidiabetic medication during follow-up. |
| Secondary | Worsening glycemic control. | 3 years | Occurrence of worsening glycemic control during follow-up |
| Secondary | Marked decline in kidney function | 3 years | eGFR \<10 mL/min/1.73 m², confirmed on at least two consecutive measurements during follow-up. |
| Secondary | Initiation of dialysis or kidney transplantation. | 3 years | Initiation of maintenance dialysis or receipt of kidney transplantation during follow-up. |
| Secondary | Statin-associated muscle symptoms requiring a change in regimen or dose. | 3 years | Occurrence of statin-associated muscle symptoms requiring a change in statin regimen or dose during follow-up. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07524101/registered